News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
710,330 Results
Type
Article (42091)
Company Profile (436)
Press Release (667803)
Section
Business (208656)
Career Advice (2020)
Deals (35999)
Drug Delivery (102)
Drug Development (83532)
Employer Resources (171)
FDA (16396)
Job Trends (15081)
News (352612)
Policy (33033)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2633)
Accelerated approval (3)
Adcomms (24)
Allergies (80)
Alliances (50878)
ALS (83)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (113)
Approvals (16368)
Artificial intelligence (230)
Autoimmune disease (13)
Automation (14)
Bankruptcy (370)
Best Places to Work (11846)
BIOSECURE Act (18)
Biosimilars (96)
Biotechnology (330)
Bladder cancer (55)
Brain cancer (24)
Breast cancer (244)
Cancer (1877)
Cardiovascular disease (150)
Career advice (1684)
Career pathing (28)
CAR-T (139)
Cell therapy (402)
Cervical cancer (14)
Clinical research (67287)
Collaboration (759)
Compensation (424)
Complete response letters (23)
COVID-19 (2635)
CRISPR (38)
C-suite (199)
Cystic fibrosis (102)
Data (1800)
Decentralized trials (2)
Denatured (24)
Depression (44)
Diabetes (232)
Diagnostics (6366)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (113)
Drug pricing (103)
Drug shortages (26)
Duchenne muscular dystrophy (75)
Earnings (87074)
Editorial (34)
Employer branding (21)
Employer resources (147)
Events (114869)
Executive appointments (620)
FDA (17415)
Featured Employer (56)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (673)
Gene editing (98)
Generative AI (19)
Gene therapy (286)
GLP-1 (702)
Government (4457)
Grass and pollen (4)
Guidances (47)
Healthcare (19127)
Huntington's disease (23)
IgA nephropathy (23)
Immunology and inflammation (102)
Indications (25)
Infectious disease (2759)
Inflammatory bowel disease (136)
Inflation Reduction Act (11)
Influenza (44)
Intellectual property (73)
Interviews (311)
IPO (16761)
IRA (43)
Job creations (3699)
Job search strategy (1433)
Kidney cancer (9)
Labor market (29)
Layoffs (471)
Leadership (15)
Legal (7972)
Liver cancer (71)
Lung cancer (271)
Lymphoma (125)
Machine learning (2)
Management (58)
Manufacturing (262)
MASH (60)
Medical device (13446)
Medtech (13451)
Mergers & acquisitions (19660)
Metabolic disorders (627)
Multiple sclerosis (63)
NASH (19)
Neurodegenerative disease (82)
Neuropsychiatric disorders (29)
Neuroscience (1854)
NextGen: Class of 2025 (6753)
Non-profit (4550)
Northern California (2287)
Now hiring (36)
Obesity (348)
Opinion (216)
Ovarian cancer (63)
Pain (75)
Pancreatic cancer (72)
Parkinson's disease (128)
Partnered (17)
Patents (187)
Patient recruitment (85)
Peanut (46)
People (58348)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21131)
Phase II (29699)
Phase III (21954)
Pipeline (862)
Podcasts (68)
Policy (110)
Postmarket research (2601)
Preclinical (8996)
Press Release (67)
Prostate cancer (89)
Psychedelics (37)
Radiopharmaceuticals (258)
Rare diseases (365)
Real estate (6006)
Recruiting (66)
Regulatory (22496)
Reports (43)
Research institute (2411)
Resumes & cover letters (351)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (122)
Series B (74)
Service/supplier (11)
Sickle cell disease (54)
Southern California (1986)
Special edition (17)
Sponsored (29)
Startups (3755)
State (2)
Stomach cancer (13)
Supply chain (59)
The Weekly (43)
United States (20464)
Vaccines (657)
Venture capitalists (36)
Webinars (13)
Weight loss (240)
Women's health (32)
Worklife (15)
Date
Today (69)
Last 7 days (606)
Last 30 days (3008)
Last 365 days (34975)
2025 (6530)
2024 (36305)
2023 (41017)
2022 (52279)
2021 (56770)
2020 (54923)
2019 (47421)
2018 (35701)
2017 (33031)
2016 (32352)
2015 (38402)
2014 (32188)
2013 (27111)
2012 (29225)
2011 (29865)
2010 (27993)
Location
Africa (735)
Alabama (53)
Alaska (7)
Arizona (223)
Arkansas (13)
Asia (39013)
Australia (6495)
California (5297)
Canada (1804)
China (433)
Colorado (242)
Connecticut (260)
Delaware (120)
Europe (85190)
Florida (772)
Georgia (180)
Idaho (57)
Illinois (486)
India (22)
Indiana (285)
Iowa (8)
Japan (132)
Kansas (102)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (812)
Massachusetts (4082)
Michigan (207)
Minnesota (359)
Mississippi (2)
Missouri (73)
Montana (29)
Nebraska (25)
Nevada (54)
New Hampshire (65)
New Jersey (1506)
New Mexico (29)
New York (1500)
North Carolina (947)
North Dakota (7)
Northern California (2287)
Ohio (184)
Oklahoma (13)
Oregon (36)
Pennsylvania (1191)
Puerto Rico (6)
Rhode Island (25)
South America (1107)
South Carolina (16)
South Dakota (1)
Southern California (1986)
Tennessee (87)
Texas (779)
Utah (161)
Virginia (124)
Washington D.C. (58)
Washington State (512)
West Virginia (3)
Wisconsin (46)
710,330 Results for "allos therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
March 4, 2025
·
7 min read
Press Releases
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
February 24, 2025
·
6 min read
Press Releases
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
January 23, 2025
·
4 min read
Press Releases
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
January 28, 2025
·
7 min read
Press Releases
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
December 9, 2024
·
12 min read
Press Releases
Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked iPSC Cell Lines facilitating cost-effective cell therapy development
February 17, 2025
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
February 14, 2025
·
11 min read
Biotech Beach
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.
March 13, 2024
·
6 min read
Press Releases
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
December 9, 2024
·
9 min read
1 of 71,033
Next
